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Data on the impact of human papillomavirus (HPV) vaccination on the population HPV prevalence are largely obtained from
women. We assessed the impact of the girls-only HPV16/18 vaccination program in the Netherlands that started in 2009,
on trends in HPV prevalence among women and heterosexual men, using data from the PASSYON study. In this cross-
sectional study, the HPV prevalence among 16- to 24-year-old visitors to sexually transmitted infection clinics was
assessed in 2009, 2011, 2013, and 2015. We compared the genital postvaccination HPV prevalence with the
prevaccination prevalence (2009) using Poisson GEE models. In total, we included 4,996 women and 1,901 heterosexual
men. The percentage of women who reported to be vaccinated increased from 2.3% in 2009 to 37% in 2015. Among all
women, the HPV16/18 prevalence decreased from 23% prevaccination to 15% in 2015 (adjusted prevalence ratio [aPR]
0.62, ptrend < 0.01). Among heterosexual men, the HPV16/18 prevalence decreased from 17% prevaccination to 11% in
2015 (aPR 0.52, ptrend < 0.01). Of the heterosexual men with a steady partner, HPV16/18 prevalence was lower among
those whose steady partner had been vaccine-eligible in the national immunization program (aPR 0.13). Among
unvaccinated women, the HPV16/18 prevalence in 2015 was not different from prevaccination. The decreasing HPV16/18
prevalence among heterosexual men and the reduced HPV16/18 prevalence among heterosexual men with a vaccine-
eligible steady partner strongly suggests herd protection from girls-only vaccination. Absence of notable herd effects
among unvaccinated women 6 years postvaccination may be due to the moderate vaccine uptake among girls in the
Netherlands.
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What’s new?
Human papillomavirus (HPV) is a sexually transmitted virus that plays a causal role in the development of anogenital and
oropharyngeal cancers in both men and women. The population-level impact of HPV vaccination programs on the HPV
prevalence has however mainly been studied in women. This study shows decreasing trends in the HPV16 and HPV18
prevalence among both women and heterosexual men after the introduction of a girls-only HPV16/18 vaccination program in
the Netherlands. The ﬁndings provide compelling evidence for herd protection in men. Because HPV16/18 are the most
oncogenic types, HPV-related cancers are expected to decline in both sexes after girls-only HPV vaccination.
Introduction
Human papillomavirus (HPV) is a sexually transmitted virus
that plays a causal role in the development of anogenital and
oropharyngeal cancers in both men and women.1 To prevent
HPV-related cancers, many countries have included HPV vac-
cination in their national immunization program (NIP), using
one of the available vaccines that provide direct protection
against two, four, or nine HPV types, all including HPV16 and
HPV18.2
In the Netherlands, the bivalent vaccine (Cervarix®, GSK) is
used in the NIP; to date, this has been a girls-only program.3 In
2009, there was a catch-up campaign for girls born from 1993
to 1996 with 52% that completed the 3-dose schedule.4 Routine
HPV vaccination was introduced in 2010 for girls in the year
they turn 13, with an initial 3-dose uptake of 56% (birth cohort
1997). The uptake increased to 61% for birth cohort 2001, but
decreased again to 53% for birth cohort 2002. In 2014, routine
HPV vaccination changed to a 2-dose schedule.5
We previously reported on direct bivalent HPV vaccine
effectiveness using cross-sectional data from female sexually
transmitted infection (STI) clinic visitors. We showed high
effectiveness against the vaccine types HPV16 and HPV18
and cross-protection against other oncogenic HPV types.6
These ﬁndings were reiterated in a longitudinal cohort study
among vaccine-eligible girls.7
The population-level impact of HPV vaccination programs
also includes possible indirect effects, such as herd protection. So
far, the population-level impact of HPV vaccination programs on
the HPV prevalence has mainly been studied among women. Sur-
veillance studies have shown a decrease in the HPV16/18 preva-
lence since the introduction of vaccination.8 Some studies have
also shown decreases in the HPV16/18 prevalence among unvac-
cinated women.9–11 This decrease among unvaccinated women is
attributed to herd protection in men, yet there is limited informa-
tion about trends in HPV prevalence among men, especially after
bivalent HPV vaccination. One study has shown that the
HPV16/18 prevalence in urine samples from men decreased from
5.0% prevaccination to 1.1% 2–4 years post girls-only bivalent
vaccination.12 However, since the method of sample collection
had changed, the authors were cautious in drawing conclusions.
Because HPV16/18 are associated with the majority of HPV-
related cancers in men,1 demonstrating herd protection for these
types in heterosexual men is important for assessing the overall
health gain from a girls-only HPV vaccination program.13,14
We assessed the population-level impact of the girls-only
bivalent HPV vaccination program in the Netherlands by study-
ing trends in the prevalence of HPV vaccine and cross protective
types from prevaccination up to 6 years postvaccination. We
included women as well as heterosexual men, and focused on
unvaccinated women and heterosexual men with vaccine-eligible
partners to study herd protection. We used data from the PASS-
YON (PApillomavirus Surveillance among STI clinic YOung-
sters in the Netherlands) study, a biennial cross-sectional study
among visitors to STI clinics that had been designed to monitor
the HPV vaccination program in the Netherlands.
Materials and Methods
Study design and population
The PASSYON study started in 2009 when HPV vaccination
was implemented in the Netherlands. Young (16- to 24-year-
old) people who visited STI clinics throughout the Nether-
lands were asked to participate in the study. In addition to the
routine STI consultation, participants were asked to ﬁll out a
questionnaire regarding demographics, sexual behavior and
vaccination status. Moreover, they were asked to provide a
self-collected genital swab for HPV testing. Women were
instructed to insert a swab (Copan Diagnostics, Italy) about
4 cm into the vagina until resistance was felt and to turn it
around along the walls of the vagina. Men were instructed to
ﬁrmly move the swab up and down the entire shaft, the glans,
the coronal sulcus and under the foreskin of the penis. More
details about the PASSYON study have been published previ-
ously.15 To explore trends in the HPV prevalence after imple-
mentation of HPV vaccination, the PASSYON study was
repeated in 2011, 2013 and 2015 using the same study proto-
col. Participants could be included in multiple study rounds,
but the probability of repeated consultations is low as we sam-
pled for only 2 months in the same period every other year
(Fig. 1). The Dutch Medical Research Involving Human Sub-
jects Act (Dutch acronym: WMO) does not apply for our
study, because only for-the-researchers-anonymized-data were
used and there were no (medical) interventions other than
routine care. The Medical Ethical Committee of the University
of Utrecht, the Netherlands, provided a waiver for full medical
ethical review (protocol number 08/397). Data were obtained
using a unique code per person and all participants gave
informed consent.
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Laboratory methods
HPV testing protocols were constant across all years and
described in detail elsewere.15 Brieﬂy, DNA was extracted
using the MagnaPure platform (Total Nucleic Acid Isolation
Kit, Roche, the Netherlands) and HPV-DNA was ampliﬁed
using the SPF10 primer set and detected using the DNA
enzyme-linked immunoassay (HPV-DEIA, DDL Diagnostics
Laboratory, the Netherlands). Positive samples were geno-
typed with line-probe assay (HPV-LiPA25, DDL Diagnostics
Laboratory, the Netherlands), which is able to detect 25 HPV
types, including HPV16 and HPV18.
Statistical analyses
Only participants with a genital swab were included in the
analyses. All analyses were performed separately for all
women (irrespective of vaccination status), heterosexual men
(based on self-identiﬁed sexual preference) and unvaccinated
women (based on self-reported vaccination status).
We calculated the prevalence and Wilson score 95% conﬁ-
dence interval (95% CI) of HPV16 and HPV18 (combined
and separately) for each PASSYON year and performed a
crude Cochran-Armitage Trend Test. Next, we compared the
HPV prevalence of the postvaccination periods (2011, 2013
and 2015) with the prevaccination period (2009) and calcu-
lated prevalence ratios (PRs) using a Poisson model with
robust error variance. This results in comparable estimates as
compared to log-binomial regression, and improves numerical
convergence.16 Additionally, because we assumed identical
effects of covariates on the prevalence of HPV types included
in the analyses, we made use of a generalized estimating equa-
tion (GEE) model with an exchangeable correlation structure.
This allows efﬁcient estimation of coefﬁcients and calculation
of the population-averaged effect of study year on the HPV
prevalence, either type-speciﬁc or pooled (as a weighted aver-
age).17 Linear trends over time were assessed by including
PASSYON year as a continuous variable in the model. These
analyses were adjusted for age (16–20 and 21–24 years) and
possible confounders, presented in Table 1. The variables age
at sexual debut and number of sex partners in the past
6 months and lifetime were categorized for analyses purposes
based on knowledge about the HPV risk and size of each cate-
gory. The selection of confounders was based on the following
procedure. First, we explored the association with PASSYON
year and high-risk HPV (hrHPV) positivity (being positive for
HPV16/18/31/33/35/39/45/51/52/56/58/59), using Chi-square
tests. Using hrHPV instead of HPV16/18 positivity for the
selection of confounders gave more power to detect possible
associations. Variables associated with PASSYON year and
hrHPV positivity (p < 0.05) in univariable analyses were
selected. Second, because sexual risk behavior variables were
highly correlated, we used computerized selection models
(stepwise with p < 0.05 as entry and stay criteria) with hrHPV
positivity as an outcome and the sexual risk behavior variables
that were selected as independent variables. Variables that
were included in the ﬁnal selection model were evaluated as
possible confounders to adjust for in the Poisson GEE models
for comparing HPV prevalence between study rounds. For all
women, we also adjusted for self-reported vaccination status
to assess if possible trends in HPV prevalence over time was
explained by an increasing proportion of vaccinated women
in our study population. Although HPV vaccination was not
offered to men in the Dutch NIP, it is possible that men were
vaccinated elsewhere. In sensitivity analyses, we excluded het-
erosexual men who reported to have been HPV vaccinated.
To study the population-level impact and herd protection for
the cross-protective types HPV31/33/459, we repeated the ana-
lyses by also including these types.
Because women who were offered vaccination in the Neth-
erlands (women born in 1993 or later), were aging over the
span of the PASSYON study, the vaccination coverage by age
category differed over the years. We assessed for effect modiﬁ-
cation by age category by including an interaction term
Figure 1. Human papillomavirus (HPV) vaccination in the Netherlands and the PASSYON study design. Abbreviation: STI: sexually transmitted
infection. [Color ﬁgure can be viewed at wileyonlinelibrary.com]
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Table 1. Characteristics of the study population of all PASSYON years combined for all women, heterosexual men and unvaccinated women
All women Heterosexual men Unvaccinated women
N (%) N (%) N (%)
Total 4,996 1,901 3,594
Age
16–20 years 2,012 (40.3) 557 (29.3) 1,186 (33.0)
21–24 years 2,984 (59.7) 1,344 (70.7) 2,408 (67.0)
Self-defined ethnicity
Dutch 4,319 (86.5) 1,522 (80.1) 3,127 (87.1)
Not Dutch 675 (13.5) 377 (19.9) 465 (12.9)
Education level1
Low/middle 1,246 (25.1) 591 (31.2) 835 (23.3)
High 3,719 (74.9) 1,303 (68.8) 2,745 (76.7)
Sexual preference
Heterosexual 4,804 (96.2) 1,901 (100) 3,457 (96.2)
Gay or bisexual 192 (3.8) - 137 (3.8)
Age sexual debut2
≤14 years 647 (13.1) 322 (17.1) 439 (12.3)
15–16 years 2,396 (48.5) 762 (40.5) 1,697 (47.7)
≥17 years 1,898 (38.4) 799 (42.4) 1,423 (40.0)
Sex partners past 6 months3
0–1 partner 1,627 (32.6) 418 (22.0) 1,203 (33.5)
2–3 partners 2,412 (48.3) 715 (37.6) 1,721 (47.9)
4–5 partners 687 (13.8) 390 (20.5) 499 (13.9)
≥6 partners 265 (5.3) 378 (19.9) 169 (4.7)
Lifetime sex partners3
≤2 partners 570 (11.6) 105 (5.8) 396 (11.2)
3–4 partners 973 (19.8) 202 (11.1) 688 (19.4)
5–6 partners 966 (19.7) 240 (13.2) 694 (19.6)
7–14 partners 1,702 (34.7) 585 (32.2) 1,245 (35.2)
≥15 partners 693 (14.1) 687 (37.8) 516 (14.6)
Anal sex past 6 months
No 4,351 (87.6) 1,590 (84.8) 3,122 (87.3)
Yes 614 (12.4) 284 (15.2) 455 (12.7)
Notified for STI4
No 4,511 (90.6) 1,608 (85.0) 3,263 (91.1)
Yes 467 (9.4) 284 (15.0) 319 (8.9)
STI related symptoms4
No 3,799 (76.5) 1,367 (72.4) 2,721 (76.1)
Yes 1,170 (23.5) 521 (27.6) 853 (23.9)
Self-reported history of any STI
No 2,852 (57.4) 1,055 (55.7) 2,101 (58.7)
Yes 1,266 (25.5) 377 (19.9) 920 (25.7)
Never tested 851 (17.1) 462 (24.4) 558 (15.6)
Genital chlamydia infection4
No 4,283 (86.1) 1,594 (84.4) 3,098 (86.5)
Yes 694 (13.9) 294 (15.6) 482 (13.5)
Steady partner
No 2,961 (60.7) 1,037 (56.5) 2,127 (60.6)
Yes, for 0–6 months 1,102 (22.6) 475 (25.9) 801 (22.8)
Yes, for ≥6 months 813 (16.7) 324 (17.6) 583 (16.6)
(Continues)
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between PASSYON year and age category. For all women, we
again additionally adjusted for self-reported vaccination status
to assess if the possible difference in trends by age category
were explained by differences in vaccination coverage. We also
calculated the adjusted PRs (aPRs) and the trend for the age
categories separately.
If participants reported being in a relationship, the age of the
steady partner was asked. For heterosexual men, we assessed if
the steady partner had been eligible for HPV vaccination in the
Dutch NIP based on the reported age of the steady partner. We
assumed the steady partner had been eligible for vaccination if
she was ≤17 years in PASSYON round 2011, ≤19 years in PASS-
YON round 2013 and ≤ 21 years in PASSYON round 2015. If
the steady partner was older is a speciﬁc PASSYON round, we
assumed she had not been eligible for HPV vaccination in the
NIP. Also for all heterosexual men included in PASSYON round
2009, we assumed the steady partner had not been eligible for
HPV vaccination. To consider herd effects, we calculated the
combined HPV16/18 prevalence among heterosexual men by
age of the steady partner and vaccine-eligibility of the steady
partner. Next, we assessed the difference in HPV16/18 preva-
lence between heterosexual men with or without a vaccine-
eligible steady partner by using a GEE model with HPV16/18 as
an outcome and vaccine-eligibility of the steady partner as an
independent variable. This analysis was adjusted for age of the
men and age of the steady partner.
All analyses were performed using SAS version 9.4 (SAS
Institute Inc., Cary, NC, USA). We used a signiﬁcance level of
p < 0.05. We did complete case analyses, as none of the vari-
ables had more than 5% missing.
Results
Study population
A total of 7,108 women and heterosexual men participated in
the PASSYON study, of whom 6,897 (4,996 women and 1,901
Table 1. Characteristics of the study population of all PASSYON years combined for all women, heterosexual men and unvaccinated women
(Continued)
All women Heterosexual men Unvaccinated women
N (%) N (%) N (%)
Condom use past 6 months, casual partner5
Inconsistent 1,950 (39.2) 851 (44.9) 1,344 (37.5)
Consistent 1,806 (36.3) 658 (34.7) 1,361 (37.9)
No casual partners 1,224 (24.6) 385 (20.3) 882 (24.6)
Abbreviations: STI: sexually transmitted infection.
Numbers vary because of missing values.
1High educational level included school of higher general secondary education, pre-university education, university of applied sciences and university.
Low/middle educational level included all other levels of education.
2Categorized for analyses purposes. Minimum-maximum age reported: 9–24 years among (unvaccinated) women and heterosexual men.
3Categorized for analyses purposes. Maximum partners reported: 540 past 6 months and 900 lifetime partners among (unvaccinated) women; 50 past
6 months and 400 lifetime partners among heterosexual men.
4Based on information of the STI clinic visit.
5Inconsistent included reporting never, rarely and “sometimes I do, sometimes I do not” condom use. Consistent included reporting often or always
condom use.
Figure 2. Prevalence of human papillomavirus (HPV) types 16 or
18, HPV16 and HPV18 over time and p values for the crude trend
test, among (a) all women; (b) heterosexual men; (c) unvaccinated
women. Note: the p value presents the Cochran-Armitage Trend Test.
*Percentage of women and heterosexual men who reported to be
vaccinated at least once. [Color ﬁgure can be viewed at
wileyonlinelibrary.com]
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heterosexual men) delivered a genital swab and were included
in the current analysis; 1,524 in 2009, 1,775 in 2011, 1,816 in
2013 and 1,782 in 2015. The proportion of women who had
been eligible for vaccination increased from 0.4% in 2009 to
5.3% in 2011, 27% in 2013 and to 57% in 2015. Of the women
who had been eligible for vaccination, 55% (n = 650) reported
to be vaccinated at least once (30 reported to be vaccinated
with 1 dose, 42 with 2 doses, 456 with 3 doses and 122 did
not know the number of doses). The proportion of all women
reporting to be vaccinated at least once increased from 2.3%
in 2009 to 37% in 2015. In total 27 heterosexual men (1.4%)
reported to be HPV vaccinated.
Characteristics of the study population of all PASSYON
years combined are presented in Table 1. In general, the indi-
cators for sexual risk behavior increased over the years among
women, heterosexual men and unvaccinated women
(Supporting Information Tables 1–3). For example, we
observed an association between lifetime sex partners and
PASSYON year; with proportions reporting ≥15 lifetime sex
partners of 12% in 2009 and 18% in 2015 among all women;
31% in 2009 and 44% in 2015 among heterosexual men; and
12% in 2009 and 19% in 2015 among unvaccinated women.
The genital chlamydia prevalence was associated with PASS-
YON study year among heterosexual men only. Supporting
Information Tables 1–3 also show the association between the
characteristics and hrHPV positivity. In general, people with
higher sexual risk behavior were more often hrHPV positive.
HPV prevalence over time
Figure 2 presents the HPV16 and HPV18 prevalence over
time and the crude trend test among all women, heterosexual
men and unvaccinated women. Among all women, the
HPV16/18 prevalence decreased from 23% in 2009 to 15% in
2015 (aPR 0.62, Table 2). Also for HPV16 and HPV18 sepa-
rately, there was a signiﬁcant decrease over time (aPR 0.59
and 0.69 respectively). When we additionally adjusted for vac-
cination status, the prevalences in 2015 were no longer signiﬁ-
cantly different from 2009. Among heterosexual men, the
combined HPV16/18 prevalence decreased from 17% in 2009
to 11% in 2015 (aPR 0.52). Also separately, HPV16 and
HPV18 prevalences were signiﬁcantly lower in 2015 compared
to 2009 (aPR 0.64 and 0.33 respectively). Excluding the 27 het-
erosexual men who reported to be vaccinated did not lead to
different results (Supporting Information Table 4). Among
unvaccinated women, we observed no trends in the HPV16 or
HPV18 prevalence.
For HPV31, HPV33 and HPV45, we only observed a
declining trend in the HPV31 prevalence among all women
Table 2. Comparing postvaccination human papillomavirus (HPV) prevalence with prevaccination prevalence (2009) and assessing the trend
among all women, heterosexual men and unvaccinated women
All women Heterosexual men Unvaccinated women
% positive (95% CI) aPR (95% CI)1 % positive (95% CI) aPR (95% CI)2 % positive (95% CI) aPR (95% CI)3
HPV16/184
2009 22.7 (20.3–25.3) Reference 16.7 (13.4–20.6) Reference 22.8 (20.2–25.6) Reference
2011 23.9 (21.6–26.3) 1.08 (0.92–1.26) 13.0 (10.3–16.2) 0.75 (0.54–1.05) 24.8 (22.3–27.5) 1.11 (0.94–1.31)
2013 18.5 (16.4–20.7) 0.79 (0.67–0.94) 7.9 (5.8–10.5) 0.44 (0.30–0.64) 21.8 (19.2–24.6) 0.90 (0.76–1.08)
2015 14.9 (13.1–16.9) 0.62 (0.52–0.74) 10.8 (8.3–13.9) 0.52 (0.36–0.75) 22.8 (19.9–26.1) 0.94 (0.78–1.14)
ptrend value
5 <0.01 <0.01 <0.01 <0.01 0.62 0.16
HPV16
2009 16.9 (14.8–19.3) Reference 11.1 (8.4–14.5) Reference 17.1 (14.8–19.7) Reference
2011 16.6 (14.7–18.8) 0.98 (0.81–1.17) 6.6 (4.7–9.1) 0.57 (0.36–0.89) 17.5 (15.3–19.9) 1.01 (0.83–1.23)
2013 11.6 (10.0–13.5) 0.66 (0.54–0.81) 5.7 (4.1–8.1) 0.49 (0.31–0.78) 13.4 (11.3–15.8) 0.73 (0.59–0.91)
2015 10.8 (9.3–12.6) 0.59 (0.48–0.73) 8.4 (6.2–11.3) 0.64 (0.42–0.98) 17.3 (14.7–20.3) 0.92 (0.74–1.14)
ptrend value
5 <0.01 <0.01 0.14 0.06 0.42 0.08
HPV18
2009 7.6 (6.2–9.3) Reference 7.0 (4.9–9.9) Reference 7.5 (6.0–9.4) Reference
2011 9.9 (8.4–11.7) 1.31 (1.00–1.71) 7.4 (5.4–10.0) 1.04 (0.64–1.67) 10.2 (8.5–12.2) 1.35 (1.01–1.79)
2013 8.7 (7.2–10.3) 1.09 (0.83–1.43) 2.5 (1.5–4.2) 0.35 (0.18–0.66) 10.6 (8.8–12.8) 1.31 (0.97–1.75)
2015 5.7 (4.6–7.1) 0.69 (0.51–0.94) 2.8 (1.6–4.7) 0.33 (0.17–0.65) 8.5 (6.6–10.7) 0.98 (0.70–1.37)
ptrend value
5 0.03 <0.01 <0.01 <0.01 0.37 0.95
Abbreviations: aPR: adjusted prevalence ratio; 95% CI: 95% confidence interval.
1Adjusted for: age, lifetime sex partners, history of any sexually transmitted infection, steady partner and condom use with casual partners.
2Adjusted for: age, lifetime sex partners, history of any sexually transmitted infection and steady partner.
3Adjusted for: age, lifetime sex partners, history of any sexually transmitted infection, and condom use with casual partners.
4Defined as positive for HPV16 or HPV18 in the percentage positive, and as a pooled estimate to calculate the aPR.
5The crude ptrend values were calculated using the Cochran-Armitage Trend Test. The adjusted ptrend values were calculated by including PASSYON year
as a continuous variable.
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(adjusted ptrend 0.01), but not among heterosexual men or
unvaccinated women. For the other HPV types, no trends
were observed except for an increasing trend of HPV45
among unvaccinated women (Supporting Information
Table 5).
The vaccination coverage over time differed by age cate-
gory; for example in 2013, 40% of the 16- to 20-year-old
women reported to be vaccinated (≥1 dose), while 4.6% of the
21- to 24-year-old women reported to be vaccinated. We
observed that the HPV16/18 prevalence among 16- to
20-year-old women decreased faster as compared to 21- to
24-year-old women (aPR 0.41 and 0.74 respectively for 2015
compared to 2009, Supporting Information Fig. 1 and Sup-
porting Information Table 6). The difference in the effect of
year by age group was statistically signiﬁcant (p < 0.01). After
additional adjustment for vaccination status, the difference
between ages was no longer statistically signiﬁcant. Among
heterosexual men and unvaccinated women, there was no sta-
tistically signiﬁcant interaction with age. Among unvaccinated
women, there were no statistically signiﬁcant trends in the
HPV16 or HPV18 prevalence for both age categories (Sup-
porting Information Table 6).
Vaccine-eligible steady partner
The proportion of heterosexual men reporting a steady part-
ner who had been eligible for HPV vaccination increased from
2.2% in 2011 to 15% in 2013 and 19% in 2015. Figure 3 shows
the combined HPV16/18 prevalence among heterosexual men
according to the age of the steady partner and vaccine-
eligibility of the steady partner. Overall, heterosexual men
whose steady partner had been vaccine-eligible were less often
HPV16/18 positive compared to heterosexual men whose
steady partner had not been vaccine-eligible in the NIP (aPR
0.13 [95% CI 0.04–0.41]).
Discussion
We estimated the population-level impact of the national
girls-only bivalent HPV vaccination program in the Nether-
lands by comparing HPV prevalence from prevaccination to
postvaccination periods among male and female visitors to
STI clinics. We showed decreasing trends in the HPV16 and
HPV18 prevalence among all women and heterosexual men,
but not among unvaccinated women separately. Of the het-
erosexual men who reported to have a steady partner,
HPV16/18 prevalence was lower among those whose steady
partner had been vaccine-eligible.
Our results provide compelling evidence for herd protec-
tion for the vaccine-types among men in the aftermath of
girls-only HPV16/18 vaccination and show that herd effects
among heterosexual men will likely precede those among
unvaccinated women. Our data offer empirical support for the
population-level impact of vaccination against the two most
oncogenic HPV types as previously predicted by
transmission-dynamic models.18
We do acknowledge some limitations. First, STI clinics
became stricter in prioritizing high-risk individuals especially
since 2015, when the funding of the STI clinics had changed.19
We indeed observed increased sexual risk behavior over time
possibly related to changes in the access policy of STI clinics.
Although we adjusted for known changes, unknown changes
in the study population may have resulted in changes in the
HPV prevalence unrelated to HPV vaccination. This could for
instance explain the observed increase in HPV16 prevalence
in 2015 compared to 2013 among heterosexual men. If partici-
pants in the postvaccination study periods were at higher
HPV risk, we may have underestimated the impact of vaccina-
tion, including declines in HPV16/18 prevalence among
unvaccinated women. However, the chlamydia prevalence did
not increase among (unvaccinated) women, suggesting that
unrecorded sexual risk behavior likely did not chance that
much among female study participants. Analyses restricted to
chlamydia positive unvaccinated women did not lead to dif-
ferent results (results not shown). Second, the use of self-
reported vaccination status may have induced bias. Among
women, we believe the bias will be minimal as we previously
showed that the HPV16 and HPV18 antibody concentrations
agreed well with the self-reported vaccination status.6 Of the
heterosexual men 1.4% reported to be HPV vaccinated. If
these men were truly vaccinated against HPV, this would lead
to an overestimation of the herd effects. However, excluding
the heterosexual men who reported to be HPV vaccinated did
not lead to different results. We also used self-reported sexual
preference to identify heterosexual men. It might be that some
men did (also) have sex with men. Such bias would have
underestimated the impact of vaccination. Third, only one
Figure 3. Prevalence of human papillomavirus (HPV) types 16 or
18 among heterosexual men who reported to have a steady partner,
by age of the steady partner and vaccine-eligibility of the steady
partner. *Vaccine-eligibility of the steady partner was based on the
reported age of the steady partner in a speciﬁc PASSYON study
round and the Dutch national immunization program. None of the
steady partners of ≥22 years had been eligible according to the
national immunization program in the Netherlands.
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prevaccination measurement was available. If there were natu-
ral ﬂuctuations in the HPV prevalence in the absence of vacci-
nation, multiple prevaccination measurements would have
been preferred to obtain an accurate estimate of the average
prevaccination prevalence and to assess possible prevaccina-
tion trends. Last, we used a population of visitors to STI
clinics who are at higher HPV risk as compared to the general
population. The results are therefore not representative of the
general Dutch population, probably underestimating the
impact of vaccination.20
The decrease in the HPV16/18 prevalence among women
in our study, coincided with an increase in the percentage of
women who reported to be vaccinated. After adjustment for
vaccination status, the HPV16/18 prevalence did not differ in
2015 as compared to 2009, indicating that the increasing pro-
portion of vaccinated women explained the decreasing HPV
prevalence. In other countries, also a decline in the HPV16/18
prevalence among women was observed after introduction of
bivalent HPV vaccination. In England, the HPV16/18 preva-
lence decreased from 18% prevaccination to 4.0% 4–5 years
postvaccination among 16 to 18-year-old sexually active
women.21 In Scotland, the HPV16/18 prevalence decreased
from 30% prevaccination to 4.5% 7 years postvaccination
among 20 to 21-year-old women who underwent their ﬁrst
cervical screening.9 The larger declines in these countries as
compared to our study could be explained by an overall lower
percentage of women vaccinated in our study (37% ≥1 dose in
2015). This reﬂects both a lower percentage of women who
had been eligible for vaccination (57% in 2015) and a lower
vaccination uptake among vaccine-eligible women (55% ≥1
dose). Among 16- to 20-year-old women, with a higher per-
centage vaccinated, we observed larger declines in the
HPV16/18 prevalence.
We also observed a decrease in the HPV16/18 prevalence
among heterosexual men since the introduction of girls-only
bivalent HPV vaccination. Our results are comparable to
Australia where a declining trend in the HPV16/18 prevalence
among heterosexual men was observed after girls-only quadri-
valent HPV vaccination.22 In Australia, also a decline in the
HPV16/18 prevalence was observed among foreign-born het-
erosexual men who had arrived from countries with a bivalent
HPV vaccination program within 2 years of study inclusion.
However, effects of exposure within those countries might
have been negligible because the majority of the HPV16/18
infections clear within 2 years.23
While the decreasing HPV16/18 prevalence among hetero-
sexual men in our study strongly suggests herd protection,
causality cannot be concluded based on ecological analyses.
Nonetheless, the decreasing prevalence in combination with a
lower HPV16/18 prevalence among men whose steady partner
had been vaccine-eligible strongly indicates that heterosexual
men receive indirect protection. With most HPV-related
penile cancers attributed to HPV16,24 cancer reductions are
also expected to occur for heterosexual men in the aftermath
of girls-only HPV vaccination. Among men who have sex
with men, large reductions in HPV-related cancers are not
expected, because they beneﬁt less from herd protection after
girls-only vaccination.25 While it is anticipated that HPV
prevalence will also decline at other anatomical sites among
heterosexual men, this has not yet been demonstrated. Given
that oropharyngeal cancers constitute the largest HPV-related
burden in men,26 showing herd effects against oral HPV is
valuable to acknowledge the ultimate impact of HPV
vaccination.
Among heterosexual men, the decline in HPV prevalence
was larger for HPV18 than for HPV16, which is in line with
data from Finland where also larger herd effects were
observed for HPV18.10 Higher herd effects for HPV18 could
be explained by a lower basic reproduction number (as a con-
sequence of a higher clearance relative to HPV16).23,27,28 Even
though HPV31/33/45 could also be expected to have a lower
basic reproduction number than HPV16, there were no signs
of herd effects for these types. This could be related to a rela-
tively low background prevalence in combination with
reduced vaccine effectiveness, resulting in limited power to
detect herd effects against cross-protective types compared to
the vaccine types.
Because the vaccination coverage of completed schedule
among vaccine-eligible women in the Netherlands is 50% to
60%,5 herd protection will not have reached its full poten-
tial.13,14 This is particularly true for herd protection in unvac-
cinated heterosexual women, which is derived from herd
protection in heterosexual men, and thus constitutes a
second-order effect. With suboptimal girls-only vaccination
coverage, vaccinating boys along with girls will not only pro-
tect boys themselves, but could also increase herd protection
to unvaccinated women.29,30 Based on modeling studies, 80%
vaccination coverage in both men and women, but not in
either sex, could eradicate the vaccine types.18
We did not ﬁnd signs of herd effects among unvaccinated
women, also not when stratiﬁed by age. Nonetheless, other
studies have observed a declining prevalence of the HPV vac-
cine types among unvaccinated women suggestive of herd
protection. In Scotland, unvaccinated women born in 1995
were less often HPV16/18 positive at their ﬁrst cervical
screening compared to women born in 1988 who were not eli-
gible for vaccination (5.3% versus 30%).9 Also in Australia
and the United States, decreases in the vaccine type prevalence
have been recorded among unvaccinated women.31,32 There
are several possible explanations for the absence of a declining
trend among unvaccinated women in our study. First, in
high-risk populations with frequent changes in sex partners,
people are more likely to encounter a HPV-positive man or
women, limiting herd effects.20 However, in Australia declines
in vaccine-type prevalence were also observed among the
high-risk group of chlamydia-positive unvaccinated women.33
Second, in Australia and Scotland, the vaccination initiation
rate was much higher: over 80% in Australia and over 90% in
Woestenberg et al. 2725
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Scotland.2 Third, the time horizon of our study (6 years post-
vaccination) might be too short to observe second-order herd
effects. In the United States, where vaccination coverage was
also limited, decreases in vaccine type prevalence among
unvaccinated women were noted 5–8 years after vaccine intro-
duction and not yet after 3–6 years.32,34
In conclusion, the declining HPV16/18 prevalence among
women is consistent with previous studies, but our ﬁndings
also provide evidence for herd protection in heterosexual men
after girls-only HPV16/18 vaccination. Due to the reduction
in the HPV16/18 prevalence among women and heterosexual
men, HPV-related cancers are expected to decline in both
sexes after girls-only HPV vaccination. The absence of mea-
surable herd effects among unvaccinated women 6 years post-
vaccination highlights once again the importance of high
vaccination coverage to optimally reduce HPV-related cancer
morbidity.
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